SONIO
20.12.2022 09:31:44 CET | Business Wire | Press release
Sonio announces a €10M fundraising through the European Innovation Council Accelerator, the leading fund in supporting European deep-tech companies. For this cohort, among 1092 projects submitted, only 78 companies were selected by the EIC Accelerator. This fundraising (€2.5M in grant and €7.5M in equity investment) comes in addition to the €5M previously raised with Elaia, OneRagtime and Bpi France in June 2022. It will support Sonio, a company that empowers fetal medicine professionals and secures pregnancy ultrasounds through AI, to accelerate the release of new features on the platform, such as embedded image recognition and genomics. A great opportunity, also, to gain momentum for the French startup’s market entry in the USA, as well as ramp up sales in Europe and India.
Sonio brings together unique expertise from the fields of fetal medicine, artificial intelligence, software development and ultrasound imaging to address the 50% of congenital malformations that are not detected before birth and improve access and quality of care for pregnant women and children. Created only a couple of years ago, the startup company leverages 5 years of R&D and clinical development at Ecole Polytechnique, the PRAIRIE Institute and Necker Hospital in Paris. It already provides a comprehensive solution to assist all fetal ultrasound practitioners, from beginners to the most seasoned experts and is already being used by over 250 healthcare professionals.
“Receiving such a significant funding from one of the most competitive accelerators in the world is a testament to the innovation Sonio brings to fetal medicine” said Cécile Brosset, Chief Executive Officer and co-Founder of Sonio. « Our hard work has been fruitful. I am now more confident than ever that we can help secure pregnancy care worldwide with collective and artificial intelligence.”
“For us this funding means more research, more clinical studies, more innovation, more patents filed in Europe and ultimately an improved quality of care for patients, wherever they are. We are eager to intensify our scientific partnerships with some of the best experts in Fetal Medicine and Artificial Intelligence.” said Rémi Besson, Chief Scientific Officer and co-Founder of Sonio.
Inspired by the company’s mission and in just 2.5 years, Sonio’s multidisciplinary team has already brought 2 products to market:
- Sonio Diagnostics, designed for expert diagnostic ultrasounds, was CE marked and found its first clients in record time.
- Sonio Pro, tailored to secure and bring more efficiency to routine pregnancy ultrasounds, was launched in October and has already convinced customers in Europe.
Several partnerships have already been signed, with Samsung France, one of the main women’s health ultrasound manufacturers, but also with specialized distributors (Lifecell in India, Manager Systems in Brazil, Dynamic Medicals in Nigeria).
“This funding from EIC will allow us to accelerate our commercial development in the USA and in Europe, thanks to faster innovation and better market access. We will also be able to initiate more distribution partnerships in countries where access to healthcare is scarce, thus helping us to fulfill our mission, which is to improve access and quality of care of women and children.” said Dagmar Nuber, Chief Business Officer and co-Founder at Sonio.
About Sonio
Founded in 2020, Sonio is the only SaaS platform that empowers healthcare professionals to secure prenatal care by combining technological innovation, medical expertise, and collective intelligence. It provides a unique Artificial Intelligence software that associates the knowledge of prenatal medicine practitioners with all types of medical, imaging, genetic and environmental data to optimize prenatal screening and diagnosis.
Created by a team of entrepreneurs, and scientific, medical and tech experts, Sonio is already used by over 250 healthcare professionals.
Sonio is committed to become an “Entreprise à Mission” – a company whose objectives in the social, societal, and environmental fields are aligned with this purpose and set out in its by-laws, as defined by the 2019 PACTE law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005108/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 02:00:00 CEST | Press release
Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 01:58:00 CEST | Press release
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform
Andersen Global styrker sine kompetencer inden for skat og global mobilitet i Tyskland2.7.2026 00:13:00 CEST | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse gennem en samarbejdsaftale med Lohr and Company (L+C), der er en erfaren skatterådgivningsvirksomhed, der leverer praktiske og fleksible løsninger inden for skattecompliance, internationale skatteforhold, global mobilitet og transfer pricing. L+C har hovedkontor i Tyskland og er også til stede i Østrig og rådgiver store multinationale selskaber, familieejede virksomheder, familievirksomheder, fonde og formuende privatpersoner. L+C blev grundlagt i 2001 og har specialiseret sig i global mobilitet, opkøb og fusioner, international skattelovgivning, rapportering mellem lande og transfer pricing, herunder rapportering i henhold til Pillar 2. Derudover bistår L+C sine kunder med trusts og fonde, skattecompliance, løn- og regnskabsadministration samt privatøkonomisk rådgivning. "Samarbejdet med Andersen Global er et vigtigt skridt i udvidelsen af vores internationale kompetencer og styrker den værdi, vi skaber for kunder, der navigerer i stadig mer
Robinhood Chooses Morpho to Power New Earn Product1.7.2026 21:15:00 CEST | Press release
Morpho now powers the infrastructure behind some of the most widely used retail financial platforms in the United States, bringing more options for onchain yield to millions of customers through the apps they already use. Morpho, the open blockchain-based credit network, today announced it will power Robinhood’s new Earn product, enabling Robinhood's millions of eligible users more options to earn yield onchain via a self-custody wallet, directly within the Robinhood app. The product will roll out progressively to Robinhood's US customer base over the coming weeks. The Robinhood Earn product aims to provide risk-adjusted yield on idle balances using USDG, a dollar-pegged stablecoin. Morpho serves as the underlying credit network, Steakhouse Financial curates the vault infrastructure supporting the product, and Robinhood Chain acts as the settlement layer. The product is delivered through a seamless experience in the Robinhood app. Morpho operates as an open network on the blockchain. L
Photonics Innovators Worldwide Invited to Compete for SPIE Prism Awards1.7.2026 20:33:00 CEST | Press release
19th annual award honors exceptional new products transforming light-based technologies SPIE, the international society of optics and photonics, invites the optics and photonics community to apply for this year’s SPIE Prism Awards, which recognize outstanding new products making waves on the market. Honorees will be announced at the highly-anticipated award ceremony on 3 February 2027 at SPIE Photonics West in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701642411/en/ SPIE Prism Awards honor exceptional new products transforming optics and photonics technologies. These awards, dubbed the “Oscars of Photonics,” provide scientists and engineers in the optics and photonics industry the opportunity to showcase their contributions to the field. Finalists and winners receive extensive print, web, and onsite promotion at SPIE Photonics West, which draws more than 22,000 researchers and industry leade
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom